Aytu Biopharma, Inc.
AYTU
$2.39
$0.0954.15%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 13.75% | -2.13% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 13.75% | -2.13% | |||
| Cost of Revenue | 3.88% | 18.44% | |||
| Gross Profit | 18.73% | -10.00% | |||
| SG&A Expenses | -4.30% | -9.86% | |||
| Depreciation & Amortization | -0.11% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.42% | -0.72% | |||
| Operating Income | 740.48% | -158.90% | |||
| Income Before Tax | 899.48% | -74.50% | |||
| Income Tax Expenses | 56.89% | -169.88% | |||
| Earnings from Continuing Operations | 492.48% | -39.16% | |||
| Earnings from Discontinued Operations | -56.10% | -67.72% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 406.85% | -46.54% | |||
| EBIT | 740.48% | -158.90% | |||
| EBITDA | 288.97% | -24.98% | |||
| EPS Basic | 406.69% | -47.10% | |||
| Normalized Basic EPS | 124.60% | -26.30% | |||
| EPS Diluted | 178.67% | -66.10% | |||
| Normalized Diluted EPS | 132.45% | -20.17% | |||
| Average Basic Shares Outstanding | 0.04% | 1.06% | |||
| Average Diluted Shares Outstanding | -3.31% | -6.75% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||